281 related articles for article (PubMed ID: 31867798)
1. Identification of novel selective Mtb-DHFR inhibitors as antitubercular agents through structure-based computational techniques.
Sharma K; Neshat N; Sharma S; Giri N; Srivastava A; Almalki F; Saifullah K; Alam MM; Shaquiquzzaman M; Akhter M
Arch Pharm (Weinheim); 2020 Feb; 353(2):e1900287. PubMed ID: 31867798
[TBL] [Abstract][Full Text] [Related]
2. Fragment Discovery for the Design of Nitrogen Heterocycles as Mycobacterium tuberculosis Dihydrofolate Reductase Inhibitors.
Shelke RU; Degani MS; Raju A; Ray MK; Rajan MG
Arch Pharm (Weinheim); 2016 Aug; 349(8):602-13. PubMed ID: 27320965
[TBL] [Abstract][Full Text] [Related]
3. Structural comparison of Mtb-DHFR and h-DHFR for design, synthesis and evaluation of selective non-pteridine analogues as antitubercular agents.
Sharma K; Tanwar O; Sharma S; Ali S; Alam MM; Zaman MS; Akhter M
Bioorg Chem; 2018 Oct; 80():319-333. PubMed ID: 29986181
[TBL] [Abstract][Full Text] [Related]
4. Rational drug design, synthesis and biological evaluation of dihydrofolate reductase inhibitors as antituberculosis agents.
Tawari NR; Bag S; Raju A; Lele AC; Bairwa R; Ray MK; Rajan MG; Nawale LU; Sarkar D; Degani MS
Future Med Chem; 2015; 7(8):979-88. PubMed ID: 26062396
[TBL] [Abstract][Full Text] [Related]
5. Preparation, biological evaluation and molecular docking study of imidazolyl dihydropyrimidines as potential Mycobacterium tuberculosis dihydrofolate reductase inhibitors.
Desai NC; Trivedi AR; Khedkar VM
Bioorg Med Chem Lett; 2016 Aug; 26(16):4030-5. PubMed ID: 27397497
[TBL] [Abstract][Full Text] [Related]
6. Expansion of a novel lead targeting M. tuberculosis DHFR as antitubercular agents.
Sharma K; Tanwar O; Deora GS; Ali S; Alam MM; Zaman MS; Krishna VS; Sriram D; Akhter M
Bioorg Med Chem; 2019 Apr; 27(7):1421-1429. PubMed ID: 30827867
[TBL] [Abstract][Full Text] [Related]
7. The identification of novel Mycobacterium tuberculosis DHFR inhibitors and the investigation of their binding preferences by using molecular modelling.
Hong W; Wang Y; Chang Z; Yang Y; Pu J; Sun T; Kaur S; Sacchettini JC; Jung H; Lin Wong W; Fah Yap L; Fong Ngeow Y; Paterson IC; Wang H
Sci Rep; 2015 Oct; 5():15328. PubMed ID: 26471125
[TBL] [Abstract][Full Text] [Related]
8. Potency boost of a
Aragaw WW; Lee BM; Yang X; Zimmerman MD; Gengenbacher M; Dartois V; Chui WK; Jackson CJ; Dick T
Proc Natl Acad Sci U S A; 2021 Jun; 118(25):. PubMed ID: 34161270
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel DHFR inhibitors for treatment of tuberculosis by combining virtual screening with in vitro activity assay.
Wang N; Ren JX; Xie Y
J Biomol Struct Dyn; 2019 Mar; 37(4):1054-1061. PubMed ID: 29504455
[No Abstract] [Full Text] [Related]
10. Structure-based design, synthesis and preliminary evaluation of selective inhibitors of dihydrofolate reductase from Mycobacterium tuberculosis.
El-Hamamsy MH; Smith AW; Thompson AS; Threadgill MD
Bioorg Med Chem; 2007 Jul; 15(13):4552-76. PubMed ID: 17451962
[TBL] [Abstract][Full Text] [Related]
11. 1,3,5-triazaspiro[5.5]undeca-2,4-dienes as selective Mycobacterium tuberculosis dihydrofolate reductase inhibitors with potent whole cell activity.
Yang X; Wedajo W; Yamada Y; Dahlroth SL; Neo JJ; Dick T; Chui WK
Eur J Med Chem; 2018 Jan; 144():262-276. PubMed ID: 29274493
[TBL] [Abstract][Full Text] [Related]
12. In silico structure-based design of a novel class of potent and selective small peptide inhibitor of Mycobacterium tuberculosis Dihydrofolate reductase, a potential target for anti-TB drug discovery.
Kumar M; Vijayakrishnan R; Subba Rao G
Mol Divers; 2010 Aug; 14(3):595-604. PubMed ID: 19697148
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, molecular docking study and biological evaluation of new pyrrole scaffolds as potential antitubercular agents for dual targeting of enoyl ACP reductase and dihydrofolate reductase.
Mahnashi MH; Avunoori S; Gopi S; Shaikh IA; Saif A; Bantun F; Faidah HS; Alhadi AA; Alshehri JH; Alharbi AA; S R PK; Joshi SD
PLoS One; 2024; 19(5):e0303173. PubMed ID: 38739587
[TBL] [Abstract][Full Text] [Related]
14. Identification of Selective Inhibitors of
Sharma VK; Bharatam PV
J Comput Biol; 2021 Jan; 28(1):43-59. PubMed ID: 32207987
[TBL] [Abstract][Full Text] [Related]
15. Structural Insights into Mycobacterium tuberculosis Rv2671 Protein as a Dihydrofolate Reductase Functional Analogue Contributing to para-Aminosalicylic Acid Resistance.
Cheng YS; Sacchettini JC
Biochemistry; 2016 Feb; 55(7):1107-19. PubMed ID: 26848874
[TBL] [Abstract][Full Text] [Related]
16. Applying the designed multiple ligands approach to inhibit dihydrofolate reductase and thioredoxin reductase for anti-proliferative activity.
Ng HL; Chen S; Chew EH; Chui WK
Eur J Med Chem; 2016 Jun; 115():63-74. PubMed ID: 26994844
[TBL] [Abstract][Full Text] [Related]
17. Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase.
Gerum AB; Ulmer JE; Jacobus DP; Jensen NP; Sherman DR; Sibley CH
Antimicrob Agents Chemother; 2002 Nov; 46(11):3362-9. PubMed ID: 12384337
[TBL] [Abstract][Full Text] [Related]
18. Linking High-Throughput Screens to Identify MoAs and Novel Inhibitors of Mycobacterium tuberculosis Dihydrofolate Reductase.
Santa Maria JP; Park Y; Yang L; Murgolo N; Altman MD; Zuck P; Adam G; Chamberlin C; Saradjian P; Dandliker P; Boshoff HIM; Barry CE; Garlisi C; Olsen DB; Young K; Glick M; Nickbarg E; Kutchukian PS
ACS Chem Biol; 2017 Sep; 12(9):2448-2456. PubMed ID: 28806050
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductases by 2,4-diamino-5-[2-methoxy-5-(omega-carboxyalkyloxy)benzyl]pyrimidines: marked improvement in potency relative to trimethoprim and species selectivity relative to piritrexim.
Rosowsky A; Forsch RA; Queener SF
J Med Chem; 2002 Jan; 45(1):233-41. PubMed ID: 11754594
[TBL] [Abstract][Full Text] [Related]
20. In silico ADMET study, docking, synthesis and antimalarial evaluation of thiazole-1,3,5-triazine derivatives as Pf-DHFR inhibitor.
Sahu S; Ghosh SK; Gahtori P; Pratap Singh U; Bhattacharyya DR; Bhat HR
Pharmacol Rep; 2019 Oct; 71(5):762-767. PubMed ID: 31351317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
